View ValuationSinopharm Group 将来の成長Future 基準チェック /16Sinopharm Group利益と収益がそれぞれ年間9%と4.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9% 9.8%なると予測されています。主要情報9.0%収益成長率9.83%EPS成長率Healthcare 収益成長18.4%収益成長率4.9%将来の株主資本利益率8.97%アナリストカバレッジGood最終更新日28 Apr 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 10Sinopharm Group Co. Ltd. to Report Q1, 2026 Results on Apr 24, 2026Sinopharm Group Co. Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026お知らせ • Mar 23Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026.お知らせ • Mar 10Sinopharm Group Co. Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Sinopharm Group Co. Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026お知らせ • Nov 28Sinopharm Group Co. Ltd. Announces Board and Committee ResignationsThe board of directors of Sinopharm Group Co. Ltd. announced that on 28 November 2025, due to the work arrangement, Mr. Zhao Bingxiang ("Mr. Zhao") tendered his resignation to the Board as a non-executive Director, the chairman (the "Chairman") of the Board, the chairman of the nomination committee of the Board (the "Nomination Committee"), the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee"), a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee") and the authorized representative (the "Authorized Representative") of the Company (pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")), and Ms. Feng Rongli ("Ms. Feng") tendered her resignation to the Board as a non-executive Director, a member of the remuneration committee of the Board and a member of the Nomination Committee. Each of the above resignations shall take effect from the appointment of their respective replacement at the general meeting of the Company.お知らせ • Oct 10Sinopharm Group Co. Ltd. to Report Nine Months, 2025 Results on Oct 24, 2025Sinopharm Group Co. Ltd. announced that they will report nine months, 2025 results on Oct 24, 2025お知らせ • Aug 12Sinopharm Group Co. Ltd. to Report First Half, 2025 Results on Aug 22, 2025Sinopharm Group Co. Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Jun 12+ 1 more updateSinopharm Group Co. Ltd. Approves Final Ordinary Cash Dividend for the Year Ended 31 December 2024, Payable No Later Than 12 August 2025Sinopharm Group Co. Ltd. at its AGM held on June 12, 2025 approved final ordinary cash dividend of RMB 0.68 per share (inclusive of tax) for the year ended 31 December 2024. The Final Dividend will be paid no later than 12 August 2025 to the Shareholders whose names appear on the register of members of the Company on 23 June 2025. Ex-dividend date of 16 June 2025.お知らせ • Apr 10Sinopharm Group Co. Ltd. to Report Q1, 2025 Results on Apr 25, 2025Sinopharm Group Co. Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025お知らせ • Mar 24+ 1 more updateSinopharm Group Co. Ltd. Proposes Distribution of Final Dividend for the Financial Year End 31 December 2024, Payable on 12 August 2025Sinopharm Group Co. Ltd. proposed distribution of final dividend for the financial year end 31 December 2024 of RMB 0.68 per share. Date of shareholders' approval: 12 June 2025. Ex-dividend date: 16 June 2025; Record date: 23 June 2025; Payment date: 12 August 2025.お知らせ • Mar 12Sinopharm Group Co. Ltd. to Report Fiscal Year 2024 Results on Mar 21, 2025Sinopharm Group Co. Ltd. announced that they will report fiscal year 2024 results on Mar 21, 2025お知らせ • Feb 12Sinopharm Group Co. Ltd. Approves Board AppointmentsSinopharm Group Co. Ltd. announced at its EGM held on February 12, 2025, the shareholders approved appointment of Mr. Sun Jinglin as an executive Director of the sixth session of the Board; Mr. Hu Ligang as a non-executive Director of the sixth session of the Board; Mr. Zu Jing as a non-executive Director of the sixth session of the Board; and Mr. Xing Yonggang as a non-executive Director of the sixth session of the Board.お知らせ • Jan 08Sinopharm Group Co. Ltd. Announces Board ResignationsSinopharm Group Co. Ltd. announced that, due to work needs, Mr. Wang Kan and Mr. Wang Peng have tendered their resignation as non-executive directors to the board on 8 January 2025. The resignations will take immediate effect.お知らせ • Oct 14Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024Sinopharm Group Co. Ltd. announced that they will report nine months, 2024 results on Oct 25, 2024お知らせ • Aug 28Sinopharm Group Co. Ltd. Announces Change in PresidentThe Board of Sinopharm Group Co. Ltd. announced that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. Mr. Liu Yong ("Mr. Liu") ceased to be the President. The above arrangements took effect immediately. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024.お知らせ • Aug 27Sinopharm Group Co. Ltd. Announces Management ChangesThe board of directors of Sinopharm Group Co. Ltd. announced that it resolved to propose to appoint Mr. Zhao Bingxiang ("Mr. Zhao") as the non-executive Director and Mr. Lian Wanyong ("Mr. Lian") as the executive Director (the "Proposed Appointment of Directors") on 27 August 2024. In accordance with the articles of association of the Company (the "Articles of Association"), the above Proposed Appointment of Directors are subject to the approval by the shareholders of the Company (the "Shareholders") at the extraordinary general meeting of the Company. The Board hereby announces that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. The Board hereby announces that on 27 August 2024, due to work needs, Mr. Yu Qingming ("Mr. Yu") ceased to be the Chairman of the Board, an executive Director as well as the chairman of the Nomination Committee, the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee") and a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee"); Mr. Liu Yong ("Mr. Liu") ceased to be an executive Director, the President and a member of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee. The above arrangements took effect immediately. China National Pharmaceutical Group Co. Ltd. will make other appointments for Mr. Yu and Mr. Liu. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024.お知らせ • Aug 09Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024Sinopharm Group Co. Ltd. announced that they will report first half, 2024 results on Aug 23, 2024お知らせ • Jun 14Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024Sinopharm Group Co. Ltd. declared final dividend of RMB 0.87 per share for the fiscal year ended December 31, 2023. Ex-dividend date is 17 June 2024. Record date is 24 June 2024Payment date is 13 August 2024.お知らせ • Apr 17Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024Sinopharm Group Co. Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024お知らせ • Mar 13Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024Sinopharm Group Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024お知らせ • Oct 14Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023Sinopharm Group Co. Ltd. announced that they will report nine months, 2023 results on Oct 27, 2023お知らせ • Sep 16Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief SupervisorSinopharm Group Co. Ltd. at its EGM held on September 15, 2023, considered and approved (if thought fit) the appointment of Mr. Guo Jinhong as a shareholder representative Supervisor of the sixth session of the Supervisory Committee, to authorize the Supervisory Committee to determine his remuneration and to authorize the chairman of the Board or any executive Director to enter into the service contract or such other documents or supplemental agreements or deeds with him. The Board also announced that the sixth session of the Supervisory Committee comprises five Supervisors, and the independent Supervisors are Ms. Guan Xiaohui and Mr. Liu Zhengdong, shareholderrepresentative Supervisor is Mr. Guo Jinhong and the employee representative Supervisors are Mr. Liu Hongbing and Ms. Lu Haiqing. The first meeting of the sixth session of the Supervisory Committee was held on 15 September 2023 and resolved to elect Ms. Guan Xiaohui as the chief Supervisor of the Supervisory Committee.お知らせ • Aug 29Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive DirectorSinopharm Group Co. Ltd. announced meanwhile, in view of the retirement of Mr. Ma Ping, a non-executive Director, the Board resolved at the same meeting to propose to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect. Mr. Ma Ping, a non-executive Director of the fifth session of the Board, will retire upon the approval of appointment of Directors of the sixth session of the Board at the extraordinary general meeting of the Company. Mr. Ma Ping has confirmed that he has no disagreement with the Board, and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders (the "Shareholders") and creditors of the Company. The Board would like to take this opportunity to express its sincere gratitude to Mr. Ma Ping for his contributions to the Company during his tenure as a Director. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect.お知らせ • Aug 16Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023Sinopharm Group Co. Ltd. announced that they will report first half, 2023 results on Aug 25, 2023お知らせ • Jun 16+ 1 more updateSinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023Sinopharm Group Co. Ltd. approves final dividend of RMB 0.82 per share for the financial year end 31 December 2022, payable on 14 August 2023. Ex-dividend date 19 June 2023 and Record date 26 June 2023.お知らせ • May 19Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive DirectorSinopharm Group Co. Ltd. (the Company) announced that on 18 May 2023, due to attainment of the term of service of independent non-executive Directors as stipulated in the Rules of Procedure of Board of Directors of the Company, Mr. Zhuo Fumin (Mr. Zhuo) tendered his resignation as an independent non-executive Director of the Company, a member of the audit committee of the Board (the Audit Committee), and a member of the nomination committee of the Board (the Nomination Committee), which shall take effect from the appointment of his replacement at the general meeting of the Company. Mr. Zhuo has confirmed that he has no disagreement with the Board and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders of the Company (the Shareholders) and creditors of the Company.業績と収益の成長予測OTCPK:SHTD.F - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028657,4819,14612,60115,270912/31/2027622,5508,3809,96213,2271312/31/2026590,6207,71115,24014,501113/31/2026574,2727,11214,60916,246N/A12/31/2025575,1687,15512,53514,138N/A9/30/2025573,5647,07818,69620,187N/A6/30/2025575,8246,81117,32518,429N/A3/31/2025578,9047,08723,16524,752N/A12/31/2024584,5087,0509,80811,546N/A9/30/2024593,0738,236-33,041-29,421N/A6/30/2024590,3468,65316,76819,506N/A3/31/2024598,3188,8848,03510,385N/A12/31/2023596,5709,05414,88917,173N/A9/30/2023591,6868,76519,02721,349N/A6/30/2023591,6268,9369,66011,931N/A3/31/2023570,0678,68814,30216,763N/A12/31/2022552,1488,52618,64820,964N/A9/30/2022546,1477,91437,50938,425N/A6/30/2022533,4037,8704922,783N/A3/31/2022528,3837,9705,3787,658N/A12/31/2021521,0517,7597,0819,308N/A9/30/2021510,0917,9304,5116,795N/A6/30/2021501,7707,8748,74310,983N/A3/31/2021474,7986,956-12,001-9,890N/A12/31/2020456,4157,1879,09911,155N/A9/30/2020440,1946,6155,9988,075N/A6/30/2020427,3726,1742,3044,522N/A3/31/2020431,9766,55424,34426,653N/A12/31/2019425,2736,251N/A18,777N/A9/30/2019406,3946,311N/A2,113N/A6/30/2019382,7176,012N/A1,744N/A3/31/2019360,7606,087N/A-3,011N/A12/31/2018344,5265,834N/A3,654N/A9/30/2018336,1135,523N/A-6,868N/A6/30/2018334,0605,606N/A2,882N/A3/31/2018318,4145,083N/A-6,249N/A12/31/2017308,3545,572N/A3,209N/A9/30/2017288,8555,217N/A-19N/A6/30/2017269,3564,861N/A-3,247N/A3/31/2017264,6914,996N/AN/AN/A12/31/2016258,3884,635N/A9,258N/A9/30/2016251,4014,515N/A11,117N/A6/30/2016244,4144,394N/A12,975N/A3/31/2016234,4993,885N/AN/AN/A12/31/2015228,6733,772N/A13,412N/A9/30/2015222,5133,548N/A9,472N/A6/30/2015216,3533,323N/A5,533N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SHTD.Fの予測収益成長率 (年間9% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: SHTD.Fの収益 ( 9% ) US市場 ( 16.9% ) よりも低い成長が予測されています。高成長収益: SHTD.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: SHTD.Fの収益 ( 4.9% ) US市場 ( 11.9% ) よりも低い成長が予測されています。高い収益成長: SHTD.Fの収益 ( 4.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SHTD.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 9 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 09:55終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sinopharm Group Co. Ltd. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。32 アナリスト機関Jason MannBarclaysBo LiBofA Global ResearchXiwan JinCCB International Securities Limited29 その他のアナリストを表示
お知らせ • Apr 10Sinopharm Group Co. Ltd. to Report Q1, 2026 Results on Apr 24, 2026Sinopharm Group Co. Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
お知らせ • Mar 23Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026.
お知らせ • Mar 10Sinopharm Group Co. Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Sinopharm Group Co. Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026
お知らせ • Nov 28Sinopharm Group Co. Ltd. Announces Board and Committee ResignationsThe board of directors of Sinopharm Group Co. Ltd. announced that on 28 November 2025, due to the work arrangement, Mr. Zhao Bingxiang ("Mr. Zhao") tendered his resignation to the Board as a non-executive Director, the chairman (the "Chairman") of the Board, the chairman of the nomination committee of the Board (the "Nomination Committee"), the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee"), a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee") and the authorized representative (the "Authorized Representative") of the Company (pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")), and Ms. Feng Rongli ("Ms. Feng") tendered her resignation to the Board as a non-executive Director, a member of the remuneration committee of the Board and a member of the Nomination Committee. Each of the above resignations shall take effect from the appointment of their respective replacement at the general meeting of the Company.
お知らせ • Oct 10Sinopharm Group Co. Ltd. to Report Nine Months, 2025 Results on Oct 24, 2025Sinopharm Group Co. Ltd. announced that they will report nine months, 2025 results on Oct 24, 2025
お知らせ • Aug 12Sinopharm Group Co. Ltd. to Report First Half, 2025 Results on Aug 22, 2025Sinopharm Group Co. Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Jun 12+ 1 more updateSinopharm Group Co. Ltd. Approves Final Ordinary Cash Dividend for the Year Ended 31 December 2024, Payable No Later Than 12 August 2025Sinopharm Group Co. Ltd. at its AGM held on June 12, 2025 approved final ordinary cash dividend of RMB 0.68 per share (inclusive of tax) for the year ended 31 December 2024. The Final Dividend will be paid no later than 12 August 2025 to the Shareholders whose names appear on the register of members of the Company on 23 June 2025. Ex-dividend date of 16 June 2025.
お知らせ • Apr 10Sinopharm Group Co. Ltd. to Report Q1, 2025 Results on Apr 25, 2025Sinopharm Group Co. Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
お知らせ • Mar 24+ 1 more updateSinopharm Group Co. Ltd. Proposes Distribution of Final Dividend for the Financial Year End 31 December 2024, Payable on 12 August 2025Sinopharm Group Co. Ltd. proposed distribution of final dividend for the financial year end 31 December 2024 of RMB 0.68 per share. Date of shareholders' approval: 12 June 2025. Ex-dividend date: 16 June 2025; Record date: 23 June 2025; Payment date: 12 August 2025.
お知らせ • Mar 12Sinopharm Group Co. Ltd. to Report Fiscal Year 2024 Results on Mar 21, 2025Sinopharm Group Co. Ltd. announced that they will report fiscal year 2024 results on Mar 21, 2025
お知らせ • Feb 12Sinopharm Group Co. Ltd. Approves Board AppointmentsSinopharm Group Co. Ltd. announced at its EGM held on February 12, 2025, the shareholders approved appointment of Mr. Sun Jinglin as an executive Director of the sixth session of the Board; Mr. Hu Ligang as a non-executive Director of the sixth session of the Board; Mr. Zu Jing as a non-executive Director of the sixth session of the Board; and Mr. Xing Yonggang as a non-executive Director of the sixth session of the Board.
お知らせ • Jan 08Sinopharm Group Co. Ltd. Announces Board ResignationsSinopharm Group Co. Ltd. announced that, due to work needs, Mr. Wang Kan and Mr. Wang Peng have tendered their resignation as non-executive directors to the board on 8 January 2025. The resignations will take immediate effect.
お知らせ • Oct 14Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024Sinopharm Group Co. Ltd. announced that they will report nine months, 2024 results on Oct 25, 2024
お知らせ • Aug 28Sinopharm Group Co. Ltd. Announces Change in PresidentThe Board of Sinopharm Group Co. Ltd. announced that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. Mr. Liu Yong ("Mr. Liu") ceased to be the President. The above arrangements took effect immediately. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024.
お知らせ • Aug 27Sinopharm Group Co. Ltd. Announces Management ChangesThe board of directors of Sinopharm Group Co. Ltd. announced that it resolved to propose to appoint Mr. Zhao Bingxiang ("Mr. Zhao") as the non-executive Director and Mr. Lian Wanyong ("Mr. Lian") as the executive Director (the "Proposed Appointment of Directors") on 27 August 2024. In accordance with the articles of association of the Company (the "Articles of Association"), the above Proposed Appointment of Directors are subject to the approval by the shareholders of the Company (the "Shareholders") at the extraordinary general meeting of the Company. The Board hereby announces that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. The Board hereby announces that on 27 August 2024, due to work needs, Mr. Yu Qingming ("Mr. Yu") ceased to be the Chairman of the Board, an executive Director as well as the chairman of the Nomination Committee, the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee") and a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee"); Mr. Liu Yong ("Mr. Liu") ceased to be an executive Director, the President and a member of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee. The above arrangements took effect immediately. China National Pharmaceutical Group Co. Ltd. will make other appointments for Mr. Yu and Mr. Liu. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024.
お知らせ • Aug 09Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024Sinopharm Group Co. Ltd. announced that they will report first half, 2024 results on Aug 23, 2024
お知らせ • Jun 14Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024Sinopharm Group Co. Ltd. declared final dividend of RMB 0.87 per share for the fiscal year ended December 31, 2023. Ex-dividend date is 17 June 2024. Record date is 24 June 2024Payment date is 13 August 2024.
お知らせ • Apr 17Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024Sinopharm Group Co. Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
お知らせ • Mar 13Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024Sinopharm Group Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024
お知らせ • Oct 14Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023Sinopharm Group Co. Ltd. announced that they will report nine months, 2023 results on Oct 27, 2023
お知らせ • Sep 16Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief SupervisorSinopharm Group Co. Ltd. at its EGM held on September 15, 2023, considered and approved (if thought fit) the appointment of Mr. Guo Jinhong as a shareholder representative Supervisor of the sixth session of the Supervisory Committee, to authorize the Supervisory Committee to determine his remuneration and to authorize the chairman of the Board or any executive Director to enter into the service contract or such other documents or supplemental agreements or deeds with him. The Board also announced that the sixth session of the Supervisory Committee comprises five Supervisors, and the independent Supervisors are Ms. Guan Xiaohui and Mr. Liu Zhengdong, shareholderrepresentative Supervisor is Mr. Guo Jinhong and the employee representative Supervisors are Mr. Liu Hongbing and Ms. Lu Haiqing. The first meeting of the sixth session of the Supervisory Committee was held on 15 September 2023 and resolved to elect Ms. Guan Xiaohui as the chief Supervisor of the Supervisory Committee.
お知らせ • Aug 29Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive DirectorSinopharm Group Co. Ltd. announced meanwhile, in view of the retirement of Mr. Ma Ping, a non-executive Director, the Board resolved at the same meeting to propose to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect. Mr. Ma Ping, a non-executive Director of the fifth session of the Board, will retire upon the approval of appointment of Directors of the sixth session of the Board at the extraordinary general meeting of the Company. Mr. Ma Ping has confirmed that he has no disagreement with the Board, and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders (the "Shareholders") and creditors of the Company. The Board would like to take this opportunity to express its sincere gratitude to Mr. Ma Ping for his contributions to the Company during his tenure as a Director. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect.
お知らせ • Aug 16Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023Sinopharm Group Co. Ltd. announced that they will report first half, 2023 results on Aug 25, 2023
お知らせ • Jun 16+ 1 more updateSinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023Sinopharm Group Co. Ltd. approves final dividend of RMB 0.82 per share for the financial year end 31 December 2022, payable on 14 August 2023. Ex-dividend date 19 June 2023 and Record date 26 June 2023.
お知らせ • May 19Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive DirectorSinopharm Group Co. Ltd. (the Company) announced that on 18 May 2023, due to attainment of the term of service of independent non-executive Directors as stipulated in the Rules of Procedure of Board of Directors of the Company, Mr. Zhuo Fumin (Mr. Zhuo) tendered his resignation as an independent non-executive Director of the Company, a member of the audit committee of the Board (the Audit Committee), and a member of the nomination committee of the Board (the Nomination Committee), which shall take effect from the appointment of his replacement at the general meeting of the Company. Mr. Zhuo has confirmed that he has no disagreement with the Board and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders of the Company (the Shareholders) and creditors of the Company.